FibroGen Company Profile (NASDAQ:FGEN)

About FibroGen (NASDAQ:FGEN)

FibroGen logoFibroGen, Inc. is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body's natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:FGEN
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.46553 billion
  • Outstanding Shares: 69,944,000
Average Prices:
  • 50 Day Moving Avg: $31.44
  • 200 Day Moving Avg: $26.84
  • 52 Week Range: $15.60 - $35.65
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -30.13
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $178.19 million
  • Price / Sales: 13.72
  • Book Value: $2.04 per share
  • Price / Book: 17.13
  • EBIDTA: ($52,180,000.00)
  • Net Margins: -37.60%
  • Return on Equity: -36.41%
  • Return on Assets: -14.13%
  • Debt-to-Equity Ratio: 0.65%
  • Current Ratio: 4.27%
  • Quick Ratio: 4.27%
  • Average Volume: 464,211 shs.
  • Beta: 1.77
  • Short Ratio: 5.7
Frequently Asked Questions for FibroGen (NASDAQ:FGEN)

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

How were FibroGen's earnings last quarter?

FibroGen, Inc (NASDAQ:FGEN) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.52) EPS for the quarter, topping the Zacks' consensus estimate of ($0.63) by $0.11. The firm had revenue of $26.89 million for the quarter, compared to analyst estimates of $26.02 million. FibroGen had a negative return on equity of 36.41% and a negative net margin of 37.60%. View FibroGen's Earnings History.

Where is FibroGen's stock going? Where will FibroGen's stock price be in 2017?

8 equities research analysts have issued twelve-month price objectives for FibroGen's shares. Their forecasts range from $37.00 to $52.00. On average, they expect FibroGen's stock price to reach $45.00 in the next twelve months. View Analyst Ratings for FibroGen.

Who are some of FibroGen's key competitors?

Who are FibroGen's key executives?

FibroGen's management team includes the folowing people:

  • Thomas B. Neff, Chairman of the Board, Chief Executive Officer, Founder
  • Pat Cotroneo, Chief Financial Officer, Vice President - Finance
  • Frank H. Valone M.D., Senior Fellow, Clinical Development
  • K. Peony Yu M.D., Chief Medical Officer
  • Jeffrey L. Edwards, Independent Director
  • Jeffrey William Henderson, Independent Director
  • Thomas F. Kearns Jr., Independent Director
  • Kalevi Kurkijarvi Ph.D., Independent Director
  • Rory B. Riggs, Independent Director

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners served as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Who owns FibroGen stock?

FibroGen's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include ECOR1 CAPITAL, LLC Total Shares: 1,322,991 (1.90%), Handelsbanken Fonder AB (0.34%), Handelsinvest Investeringsforvaltning (0.10%), Capital Impact Advisors LLC (0.05%), Woodstock Corp (0.04%) and Franklin Street Advisors Inc. NC (0.01%). Company insiders that own FibroGen stock include Frank H Md Valone, K Peony Yu, Kalevi Kurkijarvi, Miguel Madero, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr, Thomas F Kearns, Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.

Who sold FibroGen stock? Who is selling FibroGen stock?

FibroGen's stock was sold by a variety of institutional investors in the last quarter, including Capital Impact Advisors LLC. Company insiders that have sold FibroGen stock in the last year include K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Insider Buying and Selling for FibroGen.

Who bought FibroGen stock? Who is buying FibroGen stock?

FibroGen's stock was bought by a variety of institutional investors in the last quarter, including Handelsinvest Investeringsforvaltning. View Insider Buying and Selling for FibroGen.

How do I buy FibroGen stock?

Shares of FibroGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is FibroGen's stock price today?

One share of FibroGen stock can currently be purchased for approximately $34.95.

MarketBeat Community Rating for FibroGen (NASDAQ FGEN)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  134
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for FibroGen (NASDAQ:FGEN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $45.00 (28.76% upside)

Analysts' Ratings History for FibroGen (NASDAQ:FGEN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017Goldman Sachs Group, Inc. (The)DowngradeBuy -> NeutralMediumView Rating Details
7/10/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$50.00HighView Rating Details
6/26/2017Citigroup Inc.Reiterated RatingBuy$48.00HighView Rating Details
6/26/2017William BlairReiterated RatingOutperformMediumView Rating Details
6/22/2017Stifel NicolausReiterated RatingBuy$32.00 -> $38.00LowView Rating Details
1/18/2017Royal Bank Of CanadaReiterated RatingBuyN/AView Rating Details
11/9/2016Leerink SwannReiterated RatingBuy$52.00N/AView Rating Details
8/9/2016Credit Suisse Group AGReiterated RatingBuy$37.00N/AView Rating Details
9/23/2015Lake Street CapitalInitiated CoverageHold$25.00N/AView Rating Details
(Data available from 7/22/2015 forward)


Earnings History for FibroGen (NASDAQ:FGEN)
Earnings by Quarter for FibroGen (NASDAQ:FGEN)
Earnings History by Quarter for FibroGen (NASDAQ FGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.63)($0.52)$26.02 million$26.89 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.53)($0.54)$19.29 million$31.91 millionViewListenView Earnings Details
11/8/2016Q3($0.63)($0.38)$24.30 million$30.10 millionViewListenView Earnings Details
8/8/2016Q2$0.36$0.35$80.58 million$89.28 millionViewListenView Earnings Details
5/9/2016Q116($0.56)($0.45)$16.89 million$28.28 millionViewListenView Earnings Details
2/29/2016Q4($0.54)($0.85)$40.44 million$24.44 millionViewListenView Earnings Details
11/12/2015Q3($0.61)($0.74)$28.74 million$19.54 millionViewListenView Earnings Details
8/13/2015Q215$0.73$0.83$111.75 million$120.55 millionViewListenView Earnings Details
5/12/2015Q115($0.53)($0.78)$34.00 million$16.30 millionViewN/AView Earnings Details
3/26/2015Q414($0.90)($0.82)$16.49 million$16.11 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for FibroGen (NASDAQ:FGEN)
2017 EPS Consensus Estimate: ($1.96)
2018 EPS Consensus Estimate: ($1.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.77)($0.48)($0.63)
Q2 20173($0.47)($0.43)($0.45)
Q3 20173($0.46)($0.22)($0.37)
Q4 20173($0.58)($0.45)($0.52)
Q1 20181($0.87)($0.87)($0.87)
Q2 20181($0.84)($0.84)($0.84)
Q3 20181$0.77$0.77$0.77
Q4 20181($0.76)($0.76)($0.76)
(Data provided by Zacks Investment Research)


Dividend History for FibroGen (NASDAQ:FGEN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for FibroGen (NASDAQ:FGEN)
Insider Ownership Percentage: 14.90%
Institutional Ownership Percentage: 43.83%
Insider Trades by Quarter for FibroGen (NASDAQ:FGEN)
Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)
Insider Trades by Quarter for FibroGen (NASDAQ:FGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/17/2017Kalevi KurkijarviDirectorSell2,000$33.45$66,900.00View SEC Filing  
7/10/2017K Peony YuInsiderSell5,000$32.98$164,900.00View SEC Filing  
7/7/2017Thomas B NeffCEOSell38,636$33.38$1,289,669.68View SEC Filing  
7/6/2017Pat CotroneoVPSell4,000$34.00$136,000.00View SEC Filing  
7/6/2017Thomas B NeffCEOSell18,900$33.53$633,717.00View SEC Filing  
6/22/2017Pat CotroneoVPSell3,000$32.00$96,000.00View SEC Filing  
6/22/2017Thomas B NeffCEOSell38,636$31.52$1,217,806.72View SEC Filing  
6/19/2017Pat CotroneoVPSell5,500$30.00$165,000.00View SEC Filing  
6/16/2017Thomas B NeffCEOSell38,636$29.40$1,135,898.40View SEC Filing  
6/15/2017Kalevi KurkijarviDirectorSell2,000$28.50$57,000.00View SEC Filing  
6/14/2017K Peony YuInsiderSell3,721$28.95$107,722.95View SEC Filing  
6/12/2017Pat CotroneoVPSell2,891$28.75$83,116.25View SEC Filing  
6/12/2017Toshinari TamuraDirectorSell30,000$28.89$866,700.00View SEC Filing  
6/6/2017Thomas F Kearns JrDirectorSell18,000$28.71$516,780.00View SEC Filing  
5/31/2017Thomas B NeffCEOSell38,636$26.21$1,012,649.56View SEC Filing  
5/16/2017Kalevi KurkijarviDirectorSell2,000$27.40$54,800.00View SEC Filing  
5/16/2017Thomas B NeffCEOSell38,636$27.70$1,070,217.20View SEC Filing  
5/15/2017Thomas B NeffCEOSell18,900$27.75$524,475.00View SEC Filing  
5/10/2017K Peony YuInsiderSell5,000$26.38$131,900.00View SEC Filing  
4/25/2017K Peony YuInsiderSell5,000$28.00$140,000.00View SEC Filing  
4/25/2017Pat CotroneoVPSell6,500$28.00$182,000.00View SEC Filing  
4/25/2017Thomas B NeffCEOSell38,636$26.92$1,040,081.12View SEC Filing  
4/24/2017Thomas B NeffCEOSell18,900$26.35$498,015.00View SEC Filing  
4/17/2017Kalevi KurkijarviDirectorSell2,000$25.25$50,500.00View SEC Filing  
4/13/2017Thomas B NeffCEOSell38,636$24.79$957,786.44View SEC Filing  
4/4/2017Thomas B NeffCEOSell38,636$23.92$924,173.12View SEC Filing  
3/21/2017Thomas B NeffCEOSell38,636$24.34$940,400.24View SEC Filing  
3/20/2017Thomas B NeffCEOSell18,900$24.88$470,232.00View SEC Filing  
3/15/2017Thomas B NeffCEOSell38,636$25.07$968,604.52View SEC Filing  
2/16/2017Kalevi KurkijarviDirectorSell2,000$24.45$48,900.00View SEC Filing  
2/14/2017Thomas B NeffCEOSell38,636$23.94$924,945.84View SEC Filing  
2/13/2017Thomas B NeffCEOSell18,900$23.97$453,033.00View SEC Filing  
2/9/2017Thomas B NeffCEOSell37,798$23.46$886,741.08View SEC Filing  
1/27/2017Thomas B NeffCEOSell37,798$23.29$880,315.42View SEC Filing  
1/19/2017Kalevi KurkijarviDirectorSell2,000$24.90$49,800.00View SEC Filing  
1/12/2017Thomas B NeffCEOSell37,798$23.85$901,482.30View SEC Filing  
1/11/2017Pat CotroneoVPSell6,500$24.00$156,000.00View SEC Filing  
1/10/2017K Peony YuInsiderSell5,000$23.56$117,800.00View SEC Filing  
12/28/2016Thomas B NeffCEOSell37,798$20.74$783,930.52View SEC Filing  
12/16/2016Rory B RiggsDirectorSell20,000$20.87$417,400.00View SEC Filing  
12/13/2016Thomas B NeffCEOSell37,798$21.24$802,829.52View SEC Filing  
12/12/2016Pat CotroneoVPSell2,344$22.05$51,685.20View SEC Filing  
12/12/2016Thomas B NeffCEOSell18,899$21.48$405,950.52View SEC Filing  
11/29/2016Thomas B NeffCEOSell37,798$22.80$861,794.40View SEC Filing  
11/28/2016Thomas B NeffCEOSell18,899$22.74$429,763.26View SEC Filing  
11/18/2016Thomas F Kearns JrDirectorSell18,000$22.40$403,200.00View SEC Filing  
11/17/2016Thomas B NeffCEOSell37,798$22.29$842,517.42View SEC Filing  
11/1/2016Thomas B NeffCEOSell37,798$16.76$633,494.48View SEC Filing  
10/19/2016Thomas B NeffCEOSell37,798$17.75$670,914.50View SEC Filing  
10/18/2016Thomas B NeffCEOSell18,899$17.94$339,048.06View SEC Filing  
10/4/2016Thomas B NeffCEOSell18,899$20.67$390,642.33View SEC Filing  
10/3/2016Thomas B NeffCEOSell18,899$20.55$388,374.45View SEC Filing  
9/21/2016Thomas B NeffCEOSell37,798$21.66$818,704.68View SEC Filing  
9/14/2016K Peony YuInsiderSell2,345$18.66$43,757.70View SEC Filing  
9/12/2016Pat CotroneoVPSell2,345$18.22$42,725.90View SEC Filing  
9/9/2016Thomas B NeffCEOSell37,798$18.99$717,784.02View SEC Filing  
8/26/2016Thomas B NeffCEOSell37,798$17.80$672,804.40View SEC Filing  
7/27/2016Thomas B NeffCEOSell37,798$18.38$694,727.24View SEC Filing  
7/13/2016Thomas B NeffCEOSell27,000$17.50$472,500.00View SEC Filing  
6/29/2016Thomas B NeffCEOSell27,000$16.02$432,540.00View SEC Filing  
6/15/2016Pat CotroneoCFOSell1,796$16.49$29,616.04View SEC Filing  
6/15/2016Thomas B NeffCEOSell27,000$16.48$444,960.00View SEC Filing  
6/10/2016K Peony YuInsiderSell2,344$17.96$42,098.24View SEC Filing  
6/3/2016Thomas B NeffCEOSell27,000$18.99$512,730.00View SEC Filing  
5/20/2016Thomas B NeffCEOSell27,000$17.68$477,360.00View SEC Filing  
5/16/2016Pat CotroneoCFOSell6,107$17.60$107,483.20View SEC Filing  
5/3/2016Thomas B NeffCEOSell27,000$17.78$480,060.00View SEC Filing  
4/20/2016Thomas B NeffCEOSell27,000$19.98$539,460.00View SEC Filing  
4/19/2016Thomas B NeffCEOSell13,500$20.21$272,835.00View SEC Filing  
4/5/2016Thomas B NeffCEOSell27,000$21.11$569,970.00View SEC Filing  
4/1/2016Frank H Md ValoneInsiderSell10,750$21.11$226,932.50View SEC Filing  
3/22/2016Thomas B NeffCEOSell27,000$18.74$505,980.00View SEC Filing  
3/8/2016Thomas B NeffCEOSell27,000$19.62$529,740.00View SEC Filing  
3/1/2016Frank H Md ValoneInsiderSell10,750$16.84$181,030.00View SEC Filing  
2/23/2016Thomas B NeffCEOSell27,000$19.11$515,970.00View SEC Filing  
2/22/2016Thomas B NeffCEOSell13,500$19.81$267,435.00View SEC Filing  
2/16/2016Frank H. Md ValoneinsiderSell10,750$18.41$197,907.50View SEC Filing  
2/10/2016Thomas B. NeffCEOSell27,000$15.31$413,370.00View SEC Filing  
1/29/2016Thomas B. NeffCEOSell27,000$19.41$524,070.00View SEC Filing  
1/21/2016Thomas F Kearns JrDirectorSell1,572$22.08$34,709.76View SEC Filing  
1/14/2016Thomas B. NeffCEOSell27,000$23.69$639,630.00View SEC Filing  
12/24/2015Thomas F. Kearns, Jr.DirectorSell7,800$30.88$240,864.00View SEC Filing  
12/23/2015Thomas B. NeffCEOSell27,000$30.10$812,700.00View SEC Filing  
12/11/2015Thomas B. NeffCEOSell27,000$29.59$798,930.00View SEC Filing  
12/10/2015K Peony YuVPSell1,093$28.96$31,653.28View SEC Filing  
12/8/2015Miguel MaderoDirectorSell40,386$30.49$1,231,369.14View SEC Filing  
11/30/2015K Peony YuVPSell5,000$30.00$150,000.00View SEC Filing  
11/25/2015Pat CotroneoCFOSell5,000$30.00$150,000.00View SEC Filing  
11/24/2015Thomas B. NeffCEOSell13,500$28.98$391,230.00View SEC Filing  
11/24/2015Thomas F. Kearns, Jr.DirectorSell3,900$29.00$113,100.00View SEC Filing  
11/23/2015Thomas B. NeffCEOSell13,500$27.99$377,865.00View SEC Filing  
11/23/2015Thomas F. Kearns, Jr.DirectorSell3,900$28.02$109,278.00View SEC Filing  
11/17/2015K Peony YuVPSell5,000$28.00$140,000.00View SEC Filing  
11/10/2015K Peony YuVPSell5,000$25.62$128,100.00View SEC Filing  
11/9/2015K Peony YuVPSell2,500$25.00$62,500.00View SEC Filing  
11/2/2015Frank H. Md ValoneinsiderSell10,000$23.18$231,800.00View SEC Filing  
10/30/2015Thomas B. NeffCEOSell27,000$24.06$649,620.00View SEC Filing  
10/21/2015Thomas F. Kearns, Jr.DirectorSell7,800$23.83$185,874.00View SEC Filing  
10/19/2015Frank H. Md ValoneinsiderSell10,000$23.00$230,000.00View SEC Filing  
10/19/2015K Peony YuVPSell5,000$24.00$120,000.00View SEC Filing  
10/16/2015K Peony YuVPSell5,000$21.46$107,300.00View SEC Filing  
10/16/2015Thomas B. NeffCEOSell27,000$21.86$590,220.00View SEC Filing  
10/2/2015Thomas B. NeffCEOSell27,000$21.59$582,930.00View SEC Filing  
10/1/2015Frank H. Md ValoneinsiderSell10,000$21.38$213,800.00View SEC Filing  
9/18/2015Thomas B. NeffCEOSell27,000$29.10$785,700.00View SEC Filing  
9/15/2015Pat CotroneoCFOSell1,093$27.95$30,549.35View SEC Filing  
9/14/2015Rory B. RiggsDirectorSell50,000$27.61$1,380,500.00View SEC Filing  
9/11/2015Miguel MaderoDirectorSell20,600$27.66$569,796.00View SEC Filing  
9/10/2015K Peony YuVPSell1,093$27.84$30,429.12View SEC Filing  
9/10/2015Pat CotroneoCFOSell7,500$27.33$204,975.00View SEC Filing  
9/4/2015Thomas B. NeffCEOSell13,500$22.88$308,880.00View SEC Filing  
9/3/2015Thomas B. NeffCEOSell13,500$22.92$309,420.00View SEC Filing  
9/1/2015Frank H. Md ValoneinsiderSell10,000$23.58$235,800.00View SEC Filing  
7/23/2015Thomas B NeffCEOSell27,000$24.71$667,170.00View SEC Filing  
7/20/2015Frank H Md ValoneInsiderSell1,000$23.70$23,700.00View SEC Filing  
7/20/2015Pat CotroneoCFOSell7,881$23.47$184,967.07View SEC Filing  
7/9/2015Thomas B NeffCEOSell27,000$22.11$596,970.00View SEC Filing  
7/6/2015K Peony YuVPSell5,381$22.69$122,094.89View SEC Filing  
6/25/2015Thomas B NeffCEOSell27,000$23.57$636,390.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for FibroGen (NASDAQ:FGEN)
Latest Headlines for FibroGen (NASDAQ:FGEN)
DateHeadline logoCongress Could Have Major Impact on Biotech Companies - PR Newswire (press release) - July 21 at 10:03 PM logoTeligent Shares Rise on FDA Approval for Erythromycin Topical Gel ... - - July 21 at 10:03 PM logoFibroGen, Inc (NASDAQ:FGEN) Receives Consensus Rating of "Buy" from Analysts - July 21 at 11:43 AM logoBiotech Movers: Vertex Continues to Move on Data for CF Regimen - - July 20 at 4:17 PM logo$34.80 Million in Sales Expected for FibroGen, Inc (FGEN) This Quarter - July 19 at 4:54 PM logoContrasting Adamas Pharmaceuticals (ADMS) and FibroGen (NASDAQ:FGEN) - July 19 at 8:51 AM logoFibroGen, Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi Sells 2,000 Shares - July 18 at 7:52 PM logoZacks: Brokerages Expect FibroGen, Inc (NASDAQ:FGEN) Will Post Earnings of -$0.47 Per Share - July 17 at 10:49 AM logoBrokers Issue Forecasts for FibroGen, Inc's Q2 2017 Earnings (NASDAQ:FGEN) - July 13 at 10:50 AM logoFibroGen, Inc (FGEN) Insider Sells $164,900.00 in Stock - July 11 at 10:52 PM logoFibroGen, Inc (FGEN) Coverage Initiated by Analysts at Jefferies Group LLC - July 10 at 5:26 PM logoFibroGen, Inc (FGEN) VP Sells $136,000.00 in Stock - July 7 at 8:41 PM logoFibroGen, Inc (FGEN) CEO Thomas B. Neff Sells 18,900 Shares - July 7 at 8:16 PM logoThomas B. Neff Sells 38,636 Shares of FibroGen, Inc (NASDAQ:FGEN) Stock - July 7 at 7:56 PM logoFibroGen, Inc (FGEN) to Post Q2 2017 Earnings of ($0.45) Per Share, William Blair Forecasts - June 28 at 7:32 AM logoFibroGen, Inc (FGEN) Given Buy Rating at Citigroup Inc. - June 26 at 5:50 PM logoFibroGen, Inc (FGEN) Receives Consensus Recommendation of "Buy" from Analysts - June 26 at 10:53 AM logoFibroGen, Inc (FGEN) Rating Reiterated by William Blair - June 26 at 8:16 AM logoFibroGen, Inc (FGEN) Rating Increased to Strong-Buy at BidaskClub - June 24 at 7:20 PM logoFibroGen, Inc (FGEN) VP Pat Cotroneo Sells 3,000 Shares - June 23 at 7:32 PM logoInsider Selling: FibroGen, Inc (FGEN) CEO Sells 38,636 Shares of Stock - June 23 at 7:15 PM logo Analysts Expect FibroGen, Inc (FGEN) Will Announce Quarterly Sales of $34.74 Million - June 23 at 6:58 PM logoStifel Nicolaus Reiterates Buy Rating for FibroGen, Inc (FGEN) - June 22 at 8:34 PM logoFibroGen's Pamrevlumab Gets Orphan Drug Designation To Treat Pancreatic Cancer - Nasdaq - June 22 at 9:46 AM logoFibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer - June 22 at 9:46 AM logoFibroGen, Inc (FGEN) VP Sells $165,000.00 in Stock - June 21 at 8:05 PM logo Analysts Expect FibroGen, Inc (FGEN) to Post -$0.48 Earnings Per Share - June 21 at 7:46 AM logoInsider Selling: FibroGen, Inc (FGEN) Director Sells 2,000 Shares of Stock - June 19 at 7:57 PM logoFibroGen, Inc (FGEN) Insider K Peony Yu Sells 3,721 Shares - June 16 at 7:58 PM logoPat Cotroneo Sells 2,891 Shares of FibroGen Inc (FGEN) Stock - June 14 at 8:19 PM logoToshinari Tamura Sells 30,000 Shares of FibroGen, Inc (FGEN) Stock - June 14 at 7:44 AM logoAbout FibroGen, Inc.FibroGen to Present at the Goldman Sachs 38th Annual Global Healthcare Conference - June 13 at 7:23 AM logoInsider Selling: FibroGen Inc (FGEN) Director Sells 18,000 Shares of Stock - June 8 at 10:30 PM logoFibroGen (FGEN) Announces European Patent Office Decision to Maintain Patent Relating to Hypoxia-Inducible Factor ... - - June 5 at 11:15 AM logoEuropean Patent Office Maintains FibroGen Patent Relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology - June 5 at 11:14 AM logoFibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : June 2, 2017 - June 2 at 6:31 PM logoETFs with exposure to FibroGen, Inc. : June 2, 2017 - June 2 at 6:31 PM logoInsider Selling: FibroGen Inc (FGEN) CEO Sells 38,636 Shares of Stock - June 1 at 10:34 PM logo$34.74 Million in Sales Expected for FibroGen Inc (FGEN) This Quarter - May 27 at 7:33 AM logoZacks: Brokerages Anticipate FibroGen Inc (FGEN) Will Announce Earnings of -$0.48 Per Share - May 26 at 12:30 AM logoETFs with exposure to FibroGen, Inc. : May 22, 2017 - May 22 at 4:50 PM logoFibroGen, Inc. :FGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017 - May 19 at 4:56 PM logoFibroGen Inc (FGEN) Director Kalevi Kurkijarvi Sells 2,000 Shares - May 17 at 11:15 PM logoInsider Selling: FibroGen Inc (FGEN) CEO Sells 18,900 Shares of Stock - May 17 at 10:51 PM logoFibroGen Inc (FGEN) CEO Thomas B. Neff Sells 38,636 Shares - May 17 at 10:28 PM logoAkebia Secures Exclusive Access to U.S. Dialysis Patients With Vifor-Fresenius Pact - May 15 at 4:50 PM logoInsider Selling: FibroGen Inc (FGEN) Insider Sells 5,000 Shares of Stock - May 12 at 8:01 PM logoEquities Analysts Offer Predictions for FibroGen Inc's FY2017 Earnings (FGEN) - May 12 at 12:54 PM logoFibroGen Inc (FGEN) to Post Q2 2017 Earnings of ($0.47) Per Share, Leerink Swann Forecasts - May 12 at 10:21 AM logoFibroGen Inc (FGEN) Announces Quarterly Earnings Results - May 11 at 2:20 PM



FibroGen (FGEN) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by Staff